The majority of dementia-related deaths in the United States occurred in nursing homes (66.9%). 5 key findings →
Design: cross-sectional
Participants: 88,523
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The heterogeneous patterns and severity of conditions produce distinctive cumulative effects for each individual.5 Multimorbidity is associated with many adverse consequences, including death, disability, institutionalization, greater use of healthcare resources, poorer quality of life, and higher rates of adverse effects of treatment or interventions.1 Comprehensive strategies for healthcare delivery that are not disease specific, as well as interventions that target geriatric syndromes common in older adults with multimorbidity, show promise for this population,5-9 although the best approaches to decision-making and clinical management of older adults with multimorbidity remain unclear. 5 key findings →
Design: systematic review
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
The unadjusted mortality rates were 13.4% in general RC/AL and 15.8% in memory-care RC/AL with an adjusted difference of 1.3 percentage points higher mortality among memory-care RC/AL residents (p = 0.04). 5 key findings →
Design: prospective cohort
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
The 2-year rate of infection was 1.20 episodes per 100 resident days, and the hospitalization rate for infection was 0.17 admissions per 100 resident days. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Overall, 1.45% of the study cohort age ≥65 received HBMC. 5 key findings →
Design: longitudinal study
Participants: 132,147
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
The average CHADS2 score was 3.3 ± 1.3. After a diagnosis of dementia, 405 individuals (16%) persisted on warfarin therapy. 4 key findings →
Design: cohort study
Participants: 2,572
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Despite using more home health and hospital services than controls in the baseline preenrollment period, which suggests that they were sicker, participants receiving house calls had 17% lower overall Medicare costs than controls, and there was no indication of poorer quality of care, greater mortality, or underservice. 4 key findings →
Design: prospective cohort
Participants: 9,425
Evidence: high
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
We identified 107,931 beneficiaries with ≥1 month as an AL resident and 323,766 beneficiaries with ≥1 month as a LSNH resident with dementia, including 1,923,867 person-months and 4,984,405 person-months, respectively. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Among 454,508 beneficiaries diagnosed with ADRD in 2017, 250,837 (55%) were in TM and 203,671 (45%) in MA. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Older adults with hip fracture are at risk for underassessment of pain, considerable delays in analgesic administration after pain is identified, and treatment with inappropriate analgesics (e.g., meperidine) in the ED. 3 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Medicare beneficiaries with a little or a lot of trouble hearing had 18% (95% confidence interval [CI] odds ratio [OR] = 1.10-1.27) and 25% (95% CI OR = 1.07-1.47) increased odds of reporting greater difficulty with understanding Medicare, respectively, compared with those with no hearing trouble. 3 key findings →
Design: cross-sectional
Participants: 10,510
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Among 370,094 persons with dementia, 93,801 (25.4%) were in MA (mean age [SD], 86.9 [7.7], 67.6% female), 39,586 (10.7%) were ACO attributed (mean age [SD], 87.2 [7.6], 67.3% female), and 236,707 (63.9%) were in TM (mean age [SD], 87.0 [7.8], 67.6% female). 5 key findings →
Participants: 370,094
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
At year 1, persons with ADRD improved on all scales, except MMSE and functional status measures; caregivers improved on all scales. 5 key findings →
Participants: 554
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Intervention participants in all four disease groups had less hospital use and lower hospital costs nonintervention participants, which drove lower overall healthcare costs. 3 key findings →
Participants: 368
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
The aging of the European population will lead to a rapid increase in dementia cases in the coming decades, posing challenges for the organization and provision of end-of-life care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
The majority of RC/AL patients were taking five or more medications; 16.0% of these patients were receiving IPMs. 5 key findings →
Design: cross-sectional
Evidence: low
Full summary, score breakdown and related studies →
Original source
Participants: 83
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
The most important predictors of having a diagnosis of ADRD by the start of care OASIS assessment were a prior discharge diagnosis of ADRD among those admitted from an inpatient setting, and frequently exhibiting symptoms of confusion. 4 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Individuals living with dementia often have limited capacity to express their care preferences at the final stage of life, and therefore, are at risk of receiving end-of-life care that may not align with their preferences.1 While most people prefer to be at home in their final days of life,2 research has shown that individuals with dementia are less likely to die in a home or community setting compared to those without dementia.3, 4 Studies also suggest that the percentage of individuals with dementia who died in a home or community setting has been increasing over time.5, 6 This study sought to update the literature by examining the association between dementia status and site of death, and by comparing the trends in site of death between decedents with and without dementia using recent national data. 5 key findings →
Participants: 813,213
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
In most of these nonacademic healthcare delivery systems, traditional randomized clinical trial designs to evaluate effectiveness are too rigid, too expensive, and take too long to achieve results. 5 key findings →
Participants: 75
Evidence: high
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Among 738 MA and 1488 FFS participants, weighted mean age was 76 years (SD 7.0), 59% were female, and 9% had probable dementia. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Functional and cognitive impairments were markedly higher for those who died aged 90 and older- predominantly women-than for those who died aged 85 to 89. 5 key findings →
Participants: 321
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
As they mix together, they become purple.2 According to a few previous reports, PUBS often occurred in elderly women who are bedridden, chronically catheterized, and constipated.3 In addition, PUBS was found in alkaline urine and with higher bacterial counts.3,4 Because of lack of significant patient numbers, the clinical background, underlining diseases, urinanalysis, and incidence of PUBS have not been well documented. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
The agreement between the two measures of dementia differed by age: in 2017, 79.2% of hospital claims for patients aged 66–74 had a diagnosis of dementia compared to older age categories that had dementia noted in over 85% of records. 5 key findings →
Participants: 1,273,348
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Lecanemab, an anti-amyloid monoclonal antibody, has been approved for treatment of early Alzheimer's disease. 2 key findings →
Participants: 137
Evidence: low
Full summary, score breakdown and related studies →
Original source
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 34,580 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.